Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial

This study is the first to demonstrate the robust efficacy of the JAK-1 selective inhibitor upadacitinib in patients with moderate-to-severe atopic dermatitis that could not be controlled with topical therapy.

Source: Journal of Allergy and Clinical Immunology - November 27, 2019 Category: Allergy & Immunology Authors: Emma Guttman-Yassky, Diamant Tha çi, Aileen L. Pangan, H. Chih-ho Hong, Kim A. Papp, Kristian Reich, Lisa A. Beck, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Jaclyn K. Anderson, Yihua Gu, Henrique D. Teixeira, Jonathan I. Silverberg Source Type: research